JP2018525001A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525001A5
JP2018525001A5 JP2018506183A JP2018506183A JP2018525001A5 JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5 JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5
Authority
JP
Japan
Prior art keywords
cell
nucleic acid
permeable conjugate
cell permeable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525001A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045819 external-priority patent/WO2017024239A1/en
Publication of JP2018525001A publication Critical patent/JP2018525001A/ja
Publication of JP2018525001A5 publication Critical patent/JP2018525001A5/ja
Pending legal-status Critical Current

Links

JP2018506183A 2015-08-06 2016-08-05 治療用細胞内在化コンジュゲート Pending JP2018525001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201993P 2015-08-06 2015-08-06
US62/201,993 2015-08-06
PCT/US2016/045819 WO2017024239A1 (en) 2015-08-06 2016-08-05 Therapeutic cell internalizing conjugates

Publications (2)

Publication Number Publication Date
JP2018525001A JP2018525001A (ja) 2018-09-06
JP2018525001A5 true JP2018525001A5 (cg-RX-API-DMAC7.html) 2019-09-12

Family

ID=57943993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506183A Pending JP2018525001A (ja) 2015-08-06 2016-08-05 治療用細胞内在化コンジュゲート

Country Status (7)

Country Link
US (1) US20180243436A1 (cg-RX-API-DMAC7.html)
EP (1) EP3331573A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018525001A (cg-RX-API-DMAC7.html)
CN (1) CN108136042A (cg-RX-API-DMAC7.html)
AR (1) AR105641A1 (cg-RX-API-DMAC7.html)
TW (1) TW201718024A (cg-RX-API-DMAC7.html)
WO (1) WO2017024239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206475B2 (en) * 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
WO2019014648A1 (en) * 2017-07-13 2019-01-17 City Of Hope PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE
US11607457B2 (en) 2017-07-13 2023-03-21 City Of Hope Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
CN114729327A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
US20260151538A1 (en) 2022-10-26 2026-06-04 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus
WO2024151843A1 (en) * 2023-01-11 2024-07-18 The Johns Hopkins University Targeted universal delivery system of don and other drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
WO2009012359A2 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Matrix metalloprotease targeting nucleic acids
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US20110218334A1 (en) * 2008-07-11 2011-09-08 Alnylam Pharmaceuticals, Inc. PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
JP2014515094A (ja) * 2011-03-04 2014-06-26 バイオ−ラッド ラボラトリーズ,インコーポレイティド アビジン−ビオチン結合の利用によるイムノアッセイのためのシグナル増幅
US10793913B2 (en) * 2013-03-08 2020-10-06 City Of Hope Methods and compositions for treatment of breast cancer
KR102522346B1 (ko) * 2013-08-29 2023-04-17 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
US20160271268A1 (en) * 2013-11-08 2016-09-22 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery

Similar Documents

Publication Publication Date Title
Dassie et al. Current progress on aptamer-targeted oligonucleotide therapeutics
Kim et al. Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
Arnold et al. Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells
Fang et al. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach
Chen et al. Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology
Kruspe et al. Aptamer-siRNA chimeras: discovery, progress, and future prospects
Zhou et al. Aptamers: A promising chemical antibody for cancer therapy
Zhang et al. A polyvalent aptamer system for targeted drug delivery
Ray et al. Aptamers for targeted drug delivery
Mahlknecht et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
Shishparenok et al. DNA-based nanomaterials as drug delivery platforms for increasing the effect of drugs in tumors
Yoon et al. Targeted delivery of C/EBPα-saRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo
Kanwar et al. Chimeric aptamers in cancer cell-targeted drug delivery
Germer et al. RNA aptamers and their therapeutic and diagnostic applications
Thiel et al. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells
Kruspe et al. Aptamers as drug delivery vehicles
Cesarini et al. The recent blooming of therapeutic aptamers
Xu et al. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression
JP2018525381A5 (cg-RX-API-DMAC7.html)
Esposito et al. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells
Meyer et al. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells
JP2021167329A5 (cg-RX-API-DMAC7.html)
Li et al. Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation
Goldberg siRNA delivery for the treatment of ovarian cancer